Prostate Cancer

Rucaparib (Rubraca, Clovis Oncology) demonstrated promising antitumor activity in patients with metastatic castration-resistant prostate cancer (mCRPC) and a deleterious BRCA alteration, according to results of a study published online in the Journal of Clinical Oncology. Read More ›

Black men with low-risk prostate cancer who were on active surveillance had an increased risk for disease progression and definitive treatment compared with their non-Hispanic White counterparts, but not increased mortality, according to the results of a recent study. Read More ›

Oral relugolix given daily is superior to standard androgen-deprivation therapy (ADT) with leuprolide (Lupron) in men with advanced prostate cancer, according to the results of the phase 3 HERO study, which were reported at the ASCO 2020 virtual annual meeting and published online before the meeting (Shore ND, et al. N Engl J Med. 2020;382:2187-2196). Read More ›

arly results from the phase 2 TheraP clinical trial show that the targeted radiation therapy ¹⁷⁷Lutetium PSMA-617 (Lu-PSMA) significantly improved prostate-specific antigen (PSA) response compared with standard cabazitaxel in men with metastatic castration-resistant prostate cancer (CRPC) that progressed after docetaxel therapy. Read More ›

Treatment with cabozantinib (Cabometyx), a kinase inhibitor, plus atezolizumab (Tecentriq), a PD-L1 inhibitor, led to clinically meaningful activity in men with metastatic castration-resistant prostate cancer (CRPC), including those with high-risk clinical features, according to the results of the phase 1b COSMIC-021 trial. Read More ›

Treatment with a combination of pembrolizumab (Keytruda) and enzalutamide (Xtandi) continues to show substantial activity in patients with metastatic castration-resistant prostate cancer (CRPC) who have already been treated with abiraterone (Zytiga), according to results of a recent clinical trial, which were presented during the virtual 2020 American Urological Association Annual Meeting.

Read More ›

Circulating tumor DNA (ctDNA) analysis is a useful sequencing platform in metastatic castration-resistant prostate cancer (CRPC), and ctDNA alterations are detected in most patients with this type of prostate cancer, according to Justin Shaya, MD, Hematology/Oncology Fellow, UC San Diego Moores Cancer Center, CA.

Read More ›

Most patients in the United States who receive stereotactic body radiation therapy (SBRT) for unfavorable intermediate- or high-risk localized prostate cancer are not receiving concurrent androgen-deprivation therapy (ADT), despite national guideline recommendations that support the concurrent use of ADT with radiation therapy.

Read More ›

Positron emission tomography (PET) scanning targeted to detect prostate-specific membrane antigen (PSMA) is poised to overtake conventional imaging, according to presentations at the 2020 Genitourinary Cancers Symposium. Read More ›

On May 19, 2020, the FDA approved a new indication for olaparib (Lynparza; AstraZeneca), a PARP inhibitor, for the treatment of men with metastatic castration-resistant prostate cancer and deleterious or suspected deleterious germline or somatic HRR mutation, as determined by an FDA-approved test, whose disease progressed after enzalutamide (Xtandi) or abiraterone acetate (Zytiga) therapy. Olaparib is the first FDA-approved PARP inhibitor for prostate cancer. Read More ›